Learn about Endoscopic Sleeve Gastroplasty (ESG)
ESG is a minimally invasive endoscopic procedure designed to help selected patients pursue weight-loss goals under medical supervision. This page provides educational information about candidacy, risks, recovery, and long-term lifestyle considerations.
This is an educational resource — not medical advice. Only a qualified physician can determine whether ESG is appropriate for you.
Endoscopic Sleeve Gastroplasty, explained
Endoscopic Sleeve Gastroplasty (ESG) is a minimally invasive procedure performed through the mouth using a flexible endoscope. A device such as the Apollo OverStitch system places sutures along the stomach wall to reshape it into a narrower tube. No part of the stomach is removed and there are no external surgical incisions.
Unlike surgical sleeve gastrectomy, which permanently removes a large portion of the stomach through laparoscopic surgery, ESG is generally considered an adjustable procedure that preserves the natural anatomy of the stomach.
Endoscopic, not surgical
Performed through the mouth using a flexible endoscope. No abdominal incisions are required.
No stomach removal
Unlike surgical sleeve gastrectomy, no portion of the stomach is excised. Tissue is preserved.
Suturing technique
Full-thickness sutures reshape the stomach into a narrower tube to reduce its functional volume.
Outpatient or short-stay
Most cases are completed in 45–90 minutes under sedation, with same-day or overnight observation.
Who may be a candidate?
Candidacy for ESG depends on a range of medical, behavioral, and personal factors. The following points are general considerations — they are not a substitute for individual medical evaluation.
BMI considerations
Often discussed for adults with a BMI between 30 and 50, though individual factors matter more than BMI alone.
Medical evaluation
A clinical history, physical exam, labs, and endoscopic assessment are typically required before any decision.
Previous weight-loss attempts
Patients have usually tried supervised diet, exercise, behavioral therapy, or medications without sustained results.
Lifestyle commitment
ESG is a tool that works alongside long-term changes in nutrition, activity, and follow-up care.
Psychological readiness
Emotional and behavioral readiness to support sustainable change is an important part of evaluation.
Only a physician can determine candidacy. Information on this page is educational and does not replace an in-person evaluation by a qualified healthcare professional.
Situations where ESG may not be appropriate
Not every patient is a suitable candidate for ESG. Identifying when another path is more appropriate is an important part of responsible care. The points below are general educational considerations — only a qualified physician can determine candidacy after individual evaluation.
Significant prior gastric surgery
Patients with certain prior stomach surgeries may not be suitable candidates and may need alternative evaluation.
Large hiatal hernia or severe reflux
Anatomic factors such as a large hiatal hernia or poorly controlled GERD may make ESG less appropriate.
Active gastrointestinal disease
Active ulcers, bleeding, severe gastritis, or other untreated GI disease typically need treatment before any endoscopic procedure is considered.
Untreated eating or psychiatric disorders
Active untreated eating disorders, substance use, or unstable psychiatric conditions usually require treatment and stabilization first.
Pregnancy or planning near-term pregnancy
ESG is not performed during pregnancy; timing of any obesity treatment around family planning should be discussed with a physician.
Inability to commit to long-term follow-up
Durable outcomes depend on long-term nutrition, behavioral, and clinical follow-up. Patients unable to commit may be better served by other approaches.
Medical conditions requiring further evaluation
Cardiopulmonary disease, bleeding disorders, anesthesia risks, or other complex conditions may require additional clearance or alternative options.
Alternative paths to discuss with your physician
- Medically supervised nutrition and behavioral therapy
- Pharmacologic therapy (e.g., GLP-1 receptor agonists) under medical supervision
- Laparoscopic sleeve gastrectomy or gastric bypass for eligible patients
- Revisional bariatric procedures for prior surgical patients
- Specialist referral for reflux, eating disorder, or metabolic evaluation
A consultation roadmap
A thorough initial consultation is the foundation of safe, informed care. Below is a general overview of what patients commonly experience. Specifics may vary by individual.
- STEP 1
Medical history review
Detailed review of personal and family history, prior weight-loss attempts, medications, comorbidities, and prior procedures.
- STEP 2
Physical evaluation
Vitals, body composition assessment, and a clinical examination focused on factors relevant to bariatric endoscopy.
- STEP 3
Diagnostic testing
Blood work, upper endoscopy when indicated, and additional studies (imaging, cardiopulmonary clearance) as needed.
- STEP 4
Goal setting
An open discussion of realistic, individualized goals — including weight, health markers, and quality-of-life outcomes.
- STEP 5
Risk discussion
Transparent review of common, less common, and rare risks, plus anesthesia considerations.
- STEP 6
Treatment discussion
Step-by-step explanation of the proposed procedure, pre-procedure preparation, and post-procedure plan.
- STEP 7
Alternative options
Balanced discussion of non-procedural and surgical alternatives so patients can make an informed choice.
What ESG is not
Understanding what ESG cannot do is just as important as understanding what it can. ESG is one tool among several available for the medical management of obesity.
- Not a shortcut or a substitute for healthy habits.
- Not a guarantee of any specific weight-loss outcome.
- Not appropriate for everyone — some patients are better served by other treatments.
- Not a cure for obesity, which is a chronic, multifactorial condition.
- Not a cosmetic procedure.
A balanced look at ESG
Every procedure involves trade-offs. The lists below summarize commonly reported benefits and limitations associated with ESG in published literature.
Potential Benefits
- Minimally invasive — performed endoscopically through the mouth.
- No surgical incisions and no external scarring.
- Typically a short recovery compared with bariatric surgery.
- No removal of stomach tissue; original anatomy is largely preserved.
Limitations
- Weight-loss results vary significantly between individuals.
- Requires sustained lifestyle, nutrition, and follow-up changes.
- Some patients may need additional procedures or conversion to surgery.
- Not all insurance plans cover the procedure.
Weight-loss results vary by individual. ESG outcomes depend on adherence to lifestyle and follow-up care.
Risks to understand before considering ESG
ESG is generally considered to have a lower complication rate than surgical bariatric procedures, but no medical procedure is risk-free. Your care team should review the following risks in detail during your evaluation.
Bleeding
Uncommon but possible at suture sites.
Infection
Any procedure carries an infection risk, even when minimally invasive.
Pain and nausea
Mild to moderate abdominal pain and nausea are common in the first days.
Reflux symptoms
Some patients may experience new or worsened acid reflux.
Suture loosening
Sutures may loosen over time and a touch-up may be considered.
Need for revision
Some patients may benefit from additional endoscopic or surgical treatment.
Anesthesia-related risks
Sedation and anesthesia carry their own risks, reviewed during evaluation.
Rare serious events
Perforation and other serious complications are uncommon but possible.
A general roadmap for recovery after ESG
Recovery experiences vary by individual. The timeline below summarizes patterns commonly described in published literature and clinical practice. Always follow your own care team's instructions.
Day 1
Post-procedure observation. Clear liquids per protocol. Mild abdominal discomfort and nausea are common and usually well controlled.
Week 1
Progression from clear to full liquids. Light walking encouraged. Most patients with sedentary work begin returning to non-strenuous activities.
Week 2
Transition to puréed foods. Continued hydration, protein focus, and gradual increase in daily movement.
Month 1
Progression toward soft foods and then small portions of solid foods, guided by the care team. Early weight changes vary by individual.
Month 3
Established eating pattern with structured nutrition follow-up. Many patients incorporate regular aerobic activity and begin resistance training.
Month 6
Most weight loss to date typically occurs in the first 6–12 months. Continued behavioral and nutritional support to support durable results.
Year 1 & Beyond
Long-term follow-up focused on weight maintenance, body composition, labs, and overall health. Outcomes vary by individual.
Recovery timelines vary by patient, comorbidities, adherence, and clinical guidance.
A neutral, educational comparison
Different treatments suit different patients. The table below summarizes general differences between ESG and other commonly discussed weight-loss options. It is not a recommendation — only a qualified physician can advise on which option, if any, is appropriate for you.
| Feature | ESG | Gastric Sleeve | Mini Gastric Bypass | GLP-1 Therapy | Revisional |
|---|---|---|---|---|---|
| Approach | Endoscopic, no incisions | Laparoscopic surgery | Laparoscopic surgery | Medication (injection) | Endoscopic or surgical |
| Stomach anatomy | Preserved | ~80% removed | Bypassed + small pouch | Unchanged | Depends on prior procedure |
| Typical setting | Outpatient / short stay | Inpatient | Inpatient | Outpatient (self-administered) | Varies |
| Reversibility | Generally adjustable | Not reversible | Partially reversible | Stops with discontinuation | Case-by-case |
| Lifestyle change required | Yes | Yes | Yes | Yes | Yes |
General educational comparison. Individual outcomes vary. Discuss options with your healthcare team.
A side-by-side educational comparison
Endoscopic Sleeve Gastroplasty (ESG) and surgical sleeve gastrectomy are distinct procedures with different techniques, recovery profiles, and considerations. The table below summarizes general differences and is not a recommendation of one option over another.
| Feature | ESG (Endoscopic) | Gastric Sleeve (Surgical) |
|---|---|---|
| Procedure | Endoscopic suturing through the mouth using the Apollo OverStitch system. | Laparoscopic surgical removal of approximately 80% of the stomach. |
| Incisions | None. Performed entirely through the mouth. | Several small abdominal incisions for laparoscopic ports. |
| Recovery | Typically outpatient or short stay; staged diet over several weeks. | Inpatient stay; staged diet over several weeks and longer activity restrictions. |
| Risks | Nausea, reflux, bleeding, rare perforation, anesthesia-related risks. | Bleeding, leak at the staple line, stricture, reflux, anesthesia-related risks, and surgical risks. |
| Weight-loss expectations | Published studies report ~13–17% Total Body Weight Loss at 12 months. Results vary. | Published studies report greater average weight loss than ESG over comparable time frames. Results vary. |
| Reversibility / Anatomy | Stomach tissue is preserved; sutures are generally adjustable. | Not reversible — a portion of the stomach is permanently removed. |
| Follow-up | Long-term nutrition, behavioral, and clinical follow-up. | Long-term nutrition, behavioral, and clinical follow-up. |
Neither procedure is universally superior. Individual outcomes vary. Only a qualified physician can advise on which option, if any, is appropriate after a full medical evaluation.
Procedure-based vs medication-based approaches
GLP-1 receptor agonists (such as semaglutide and tirzepatide) and ESG are both used in the medical management of obesity, but they work in fundamentally different ways. This comparison is educational and neutral — neither approach is universally preferable.
| Consideration | ESG | GLP-1 Medications |
|---|---|---|
| Mechanism of action | Mechanical — sutures reduce stomach volume and slow gastric emptying. | Pharmacological — GLP-1 receptor agonists affect appetite signaling and gastric motility. |
| Format | One-time endoscopic procedure. | Ongoing weekly or daily self-administered injection. |
| Weight management expectations | Published studies report ~13–17% Total Body Weight Loss at 12 months. Individual results vary. | Published trials report a range of weight reductions depending on the specific medication, dose, and adherence. Individual results vary. |
| Follow-up requirements | Structured nutrition, behavioral support, and clinical follow-up. No daily medication. | Ongoing prescription, monitoring of side effects, and periodic clinical follow-up while on therapy. |
| Common risks | Nausea, abdominal pain, reflux, bleeding, rare perforation, anesthesia-related risks. | Nausea, vomiting, diarrhea, constipation, gallbladder issues, pancreatitis (rare), and other medication-specific risks. |
| Long-term considerations | Outcomes depend on lifestyle adherence; touch-up or conversion may be considered case-by-case. | Discontinuation is associated in published studies with partial weight regain in many patients; long-term therapy may be required. |
| Cost considerations | Typically a single procedure cost; insurance coverage varies. | Recurring medication cost; coverage and pricing vary widely by country and insurer. |
| Combined use | Some patients use ESG alongside medical therapy under physician guidance. | Some patients use GLP-1 therapy alongside procedural options under physician guidance. |
Some patients pursue procedural and pharmacological options sequentially or in combination under physician guidance. Only a qualified clinician can advise on what is appropriate for an individual.
Reasonable alternatives to ESG
ESG is one of several options for the medical management of obesity. The summary below is neutral and educational — it does not claim superiority of any option. Appropriateness depends on the individual.
Medically supervised lifestyle therapy
Combines structured nutrition, physical activity, and behavioral support.
Potential benefits
Non-invasive; foundational for any obesity treatment.
Limitations
May not achieve clinically significant weight loss for all patients.
GLP-1 receptor agonist medications
Examples include semaglutide and tirzepatide, prescribed and monitored by a physician.
Potential benefits
Pharmacologic appetite regulation; outpatient self-administered.
Limitations
Requires ongoing therapy; side effects and cost considerations.
Laparoscopic sleeve gastrectomy
A widely performed bariatric surgery with established long-term data.
Potential benefits
Greater average weight loss reported in published literature.
Limitations
Surgical, not reversible; removes ~80% of the stomach.
Gastric bypass / Mini-bypass
Reroutes the digestive tract; appropriate candidacy is determined clinically.
Potential benefits
May offer metabolic benefits for some patients with type 2 diabetes.
Limitations
Surgical; nutrient absorption is altered, requiring lifelong supplementation.
Endoscopic revision after prior surgery
Endoscopic suturing may be considered after prior sleeve or bypass in selected cases.
Potential benefits
Less invasive option for selected patients with weight regain.
Limitations
Not appropriate for all anatomies; outcomes vary.
Intragastric balloon
An endoscopic option for short-term weight management.
Potential benefits
Temporary, fully reversible space-occupying device.
Limitations
Removed at 6 months; weight regain after removal is common without lifestyle changes.
Factors patients often discuss with their physician
There is no online quiz that can determine whether ESG is appropriate for any individual. The points below are commonly discussed during a clinical evaluation. They are educational prompts to bring to a conversation with a qualified healthcare professional — not a self-diagnosis tool.
Your overall health profile
Existing conditions, medications, and prior procedures all influence which options are appropriate to discuss.
Your weight-management history
What has been tried (nutrition, exercise, behavioral support, medications) and how your body has responded.
Your preference around invasiveness
Some patients explore endoscopic options before considering surgery; others may be better served by surgery from the start.
Your readiness for long-term change
Any obesity treatment works best alongside sustained nutrition, activity, and follow-up changes.
Support and follow-up access
Long-term follow-up access — local or remote — is part of durable results.
Cost and coverage realities
Procedure cost, medication cost, travel, and insurance coverage all factor into a realistic plan.
Only a qualified healthcare professional can determine candidacy for any medical procedure, including ESG. Information on this page does not replace an in-person medical evaluation.
Lifestyle considerations for long-term success
ESG works alongside long-term lifestyle changes. The following areas are commonly emphasized in published obesity-care guidelines.
Nutrition
A staged diet (liquids → puréed → soft → solids) followed by a structured long-term eating plan emphasizing whole foods.
Protein intake
Adequate daily protein supports recovery and helps preserve lean body mass during weight loss.
Exercise
Gradual return to movement, building toward a routine that combines aerobic activity and resistance training.
Follow-up care
Ongoing check-ins with your medical team to monitor progress, address concerns, and adjust your plan.
Long-term success factors
Sleep, stress management, behavioral support, and a strong support network all influence durable results.
From inquiry to long-term follow-up
Understanding the full patient journey helps set expectations and supports informed decision-making.
- 1
Inquiry
You request educational information and a coordinator follows up.
- 2
Consultation
A structured conversation reviewing history, goals, and questions.
- 3
Evaluation
Clinical assessment, lab work, and indicated diagnostic studies.
- 4
Treatment Planning
Shared decision-making with risks, benefits, and alternatives discussed.
- 5
Procedure or Treatment
If indicated, the endoscopic procedure is performed by a qualified physician.
- 6
Recovery
Staged diet, gradual activity, and close early follow-up.
- 7
Long-Term Follow-Up
Ongoing nutritional, behavioral, and clinical support for sustained outcomes.
Educational insights from the clinical team
Common observations and questions encountered in clinical practice. These reflections are educational and do not constitute medical advice for any individual.
One of the most common misconceptions patients have is…
…that ESG is a 'quick fix.' ESG is a tool that can help selected patients, but durable results depend on long-term nutrition, activity, and follow-up. Patients who understand this from the start tend to do better.
Patients frequently ask about reversibility…
Because no tissue is removed, sutures can generally be adjusted or released endoscopically. That said, the goal is rarely reversal — the goal is sustained, healthy weight management with appropriate clinical support.
On comparing ESG with GLP-1 medications…
These are different tools, not competitors. Some patients respond well to medications, some to procedures, and some benefit from a combined plan. The right choice depends on the individual.
On recovery expectations…
Most patients are surprised by how quickly they feel back to baseline. The harder part is building sustainable habits — that's where structured follow-up matters most.
Insights authored and reviewed by the clinical team at Obesity Control Center. Last reviewed: June 1, 2026.
Why patients explore endoscopic weight-loss options in Tijuana
Tijuana hosts experienced bariatric and endoscopic care teams who treat a high volume of international patients. The points below describe practical support patients commonly receive — they are not claims of superiority over care available in other locations.
International Patient Support
Dedicated coordinators help international patients navigate scheduling, documentation, and on-site logistics.
Travel Planning
Guidance on ground transportation from the San Diego area, lodging recommendations, and recovery-friendly itineraries.
Coordinated Care
Pre-procedure evaluation, day-of care, and post-procedure check-ins are coordinated through a single point of contact.
Follow-Up Guidance
Structured nutrition, behavioral, and clinical follow-up — designed to continue after you return home.
Objective program criteria
The criteria below describe practical attributes of the program. They are not claims of superiority over other providers — patients are encouraged to evaluate multiple options.
Experience
Care delivered by physicians experienced in bariatric endoscopy and minimally invasive obesity treatment.
Accreditation
Procedures performed in a Joint Commission International (JCI)-accredited hospital facility.
Education
Patients receive educational materials and time to ask questions before any decision is made.
Follow-Up
Structured post-procedure follow-up addressing nutrition, behavior, and clinical check-ins.
Multidisciplinary Care
Coordination with nutrition, behavioral, and medical specialists as part of comprehensive care.
Technology
Use of the Apollo OverStitch system — an established platform for endoscopic suturing in the stomach.
Patient Support
Dedicated patient coordinators help navigate logistics, communication, and follow-up.
Standards of care at Obesity Control Center
Experienced Medical Team
Procedures performed by physicians experienced in bariatric endoscopy and metabolic care.
JCI-Accredited Facility
Care delivered in a Joint Commission International-accredited hospital environment.
Structured Follow-Up
Ongoing nutrition, behavioral, and clinical follow-up support after the procedure.
Patient Education First
Patients receive educational materials and time to ask questions before any decision is made.
Authority, accreditation, and published outcomes
EndoscopicSleeveGuide.com is the educational program of the Obesity Control Center, an internationally accredited bariatric and metabolic surgery center led by Dr. Ariel Ortiz Lagardere, MD, FACS, FASMBS.
25+
Years of bariatric experience
Obesity Control Center
30,000+
Bariatric procedures performed
Program history
19,801+
Patients in published outcomes
Peer-reviewed literature
JCI
Accredited program
Joint Commission International
SRC
Center of Excellence
Surgical Review Corporation
GHA
Accredited
Global Healthcare Accreditation
OCC →
Obesity Control Center
JCI →
Joint Commission International
SRC →
Surgical Review Corporation
GHA →
Global Healthcare Accreditation
Sources: Sources & Verification · Published outcomes (PubMed)
Medical Review & Clinical Oversight
The educational content on this website is reviewed for medical accuracy, clarity, and patient safety by experienced bariatric and metabolic surgery professionals. The purpose of this review is to help ensure that information about obesity treatment, bariatric surgery, metabolic health, revisional surgery, endoscopic procedures, GLP-1 medications, and long-term follow-up is presented responsibly and without exaggerated claims.
Dr. Ariel Ortiz Lagardere, MD, FACS, FASMBS
Bariatric & Metabolic Surgeon
Founder and Director, Obesity Control Center
Dr. Ariel Ortiz Lagardere is a bariatric and metabolic surgeon with extensive experience in minimally invasive weight-loss surgery, metabolic disease treatment, international patient care, and surgical education. Public professional profiles describe him as board-certified in Mexico, a Fellow of the American College of Surgeons, a Fellow of the American Society for Metabolic and Bariatric Surgery, and an SRC-recognized Master Surgeon in Metabolic and Bariatric Surgery.
Dr. Arturo Martinez Gamboa, MD
Bariatric & Metabolic Surgeon
Obesity Control Center
Dr. Arturo Martinez Gamboa has been affiliated with Obesity Control Center since 2001. His publicly available professional biography describes advanced laparoscopic and bariatric training at Hospital Ramón y Cajal in Madrid, Spain. Surgical Review Corporation sources identify him as an SRC-accredited Master Surgeon in Metabolic & Bariatric Surgery and Bariatric Revisional Surgery.
Dr. Helmuth Billy, MD
Bariatric & Revisional Surgery Specialist
Ventura, California
Dr. Helmuth Billy is a bariatric surgeon specializing in laparoscopic bariatric surgery, revisional bariatric surgery, and multidisciplinary weight-loss care. Public ASMBS meeting biographies describe him as being in private practice since 1997, actively practicing bariatric surgery since 2000, serving as medical director at two MBSAQIP hospitals, and having a clinical interest in weight regain and revisional surgery.
Editorial Review Process
All medical content is periodically reviewed for accuracy, relevance, readability, and consistency with current medical knowledge and accepted bariatric and metabolic surgery principles. Content is intended to support informed decision-making and does not replace consultation with a qualified healthcare professional.
Educational Disclaimer
This website provides general educational information only. It does not provide medical advice, diagnosis, treatment recommendations, or guarantees of outcome. Candidacy for any medical, surgical, endoscopic, or medication-based treatment must be determined by a qualified healthcare professional after an individual evaluation.
Last Reviewed: June 1, 2026. Content is reviewed at least annually or when new significant evidence is published.
Sources supporting our editorial standards
- 1.American Society for Metabolic and Bariatric Surgery (ASMBS). Clinical resources and position statements on endoscopic bariatric therapies. View source ↗
- 2.International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Consensus statements on endoscopic bariatric treatments. View source ↗
- 3.National Institutes of Health (NIH) / National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Overweight and Obesity — Health Information. View source ↗
- 4.American Diabetes Association (ADA). Standards of Care in Diabetes — Obesity Management. View source ↗
- 5.American Association of Clinical Endocrinology (AACE). Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity. View source ↗
Explore other weight-loss procedures
ESG is one of several options patients may discuss with their care team. The resources below provide educational information about related procedures and therapies.
SleeveTijuana.com
Learn about laparoscopic sleeve gastrectomy options in Tijuana.
Explore Sleeve GastrectomyMiniBypassMexico.com
Educational information on mini gastric bypass procedures.
Read about Mini Gastric BypassBariatricRevision.mx
Considering a revision after prior bariatric surgery? Start here.
Learn about Bariatric RevisionGLPSurgery.com
Understand how GLP-1 therapies relate to surgical and endoscopic options.
Compare GLP-1 TherapySleevePlus.mx
An enhanced sleeve gastrectomy protocol explained for patients.
See Sleeve PlusDiabetesMagnaPlus.com
Metabolic procedures focused on patients with type 2 diabetes.
Explore Metabolic OptionsCommon questions about ESG
Educational answers grounded in published literature. None of the answers below constitute medical advice. Always consult a qualified healthcare professional about your individual situation.
Request an Educational ConsultationESG is a minimally invasive, incisionless endoscopic procedure. Using a flexible endoscope passed through the mouth, a physician places sutures along the stomach wall to reduce its functional volume. No part of the stomach is removed.
Peer-reviewed and regulatory sources
Educational claims on this page are informed by the following published studies and regulatory documents.
- 1.Abu Dayyeh BK, et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. The Lancet. 2022;400(10350):441-451. View source ↗
- 2.Hedjoudje A, et al. Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18(5):1043-1053. View source ↗
- 3.Sharaiha RZ, et al. Five-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity. Clin Gastroenterol Hepatol. 2021;19(5):1051-1057. View source ↗
- 4.Lopez-Nava G, et al. Endoscopic Sleeve Gastroplasty for Obesity: A Multicenter Study. Obes Surg. 2021. View source ↗
- 5.U.S. FDA. 510(k) Premarket Notification — Apollo ESG System. 2022. View source ↗
- 6.American Society for Metabolic and Bariatric Surgery (ASMBS). Endoscopic Bariatric Therapies — Position Statement. View source ↗
- 7.International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Endoscopic Bariatric Treatments — Consensus Statement. View source ↗
- 8.National Institutes of Health (NIH). Overweight and Obesity — Health Information. View source ↗
- 9.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Bariatric Surgery and Weight Management. View source ↗
Content Review Statement
Content on this page is reviewed by qualified healthcare professionals experienced in bariatric and metabolic treatment. Information is provided for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
Last reviewed: June 1, 2026
Have questions about ESG?
Submit your information and a patient coordinator will follow up to share educational resources and help you understand next steps. This is not a diagnosis or treatment recommendation. Only a qualified physician can determine whether ESG is appropriate for you.
+1 (619) 270-8823
info@obesitycontrolcenter.com
JCI-Accredited Facility · Tijuana, México